DU145

DU145 (DU-145) is a human prostate cancer cell line.[1] DU145, PC3, and LNCaP are considered to be the standard prostate cancer cell lines used in therapeutic research.[1]

Apoptosis in DU145 prostate cancer cells, induced by etoposide.

The DU145 cell line was derived from a central nervous system metastasis, of primary prostate adenocarcinoma origin, removed during a parieto-occipital craniotomy.[2] DU145 are not hormone-sensitive and do not express prostate-specific antigen (PSA). DU145 cells have moderate metastatic potential compared to PC3 cells, which have high metastatic potential.[3] DU145 cells are androgen receptor positive.[1]

References
  1. Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D (April 2006). "DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation". FEBS Lett. 580 (9): 2294–300. doi:10.1016/j.febslet.2006.03.041. PMID 16580667.
  2. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF (March 1978). "Isolation of a human prostate carcinoma cell line (DU 145)". Int. J. Cancer. 21 (3): 274–81. doi:10.1002/ijc.2910210305. PMID 631930.
  3. Pulukuri SM, Gondi CS, Lakka SS, et al. (October 2005). "RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo". J. Biol. Chem. 280 (43): 36529–40. doi:10.1074/jbc.M503111200. PMC 1351057. PMID 16127174.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.